Back to Results

CervoMed Inc (CRVO)

CervoMed Inc. is a clinical-stage biotechnology company focused on developing and commercializing therapies for age-related neurologic disorders. Its lead candidate, neflamapimod, is an orally administered small molecule designed to cross the blood-brain barrier and inhibit p38a, with the goal of addressing synaptic dysfunction and supporting neuron health. The program is being evaluated in several neurological conditions, including dementia with Lewy bodies, non-fluent variant primary progressive aphasia, and amyotrophic lateral sclerosis. Founded in 2010, CervoMed is headquartered in Boston, Massachusetts. The company’s common stock is listed on the NASDAQ exchange under the ticker CRVO.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ

Jump directly to the stock analysis sections supported by the latest available data.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Dividend Yield Next Earnings Date Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Free Cash Flow / Net Income
NASDAQ-CRVO
$2.70
6.8% Upside
Fair
$15.40
508.7% Upside
Bargain
Weak
0.0%
November 16, 2026
1.7x
115.5x
38.251 M
13.313 M
0.0%
63.5%
-1.4
92.2%
Valuation • Fair Value

CervoMed Inc (NASDAQ-CRVO) Fair Value by Valuation Model

Review the available estimates for CervoMed Inc (NASDAQ-CRVO), including EPV Fair Value, Comps Fair Value.

Primary Valuation Read

Fair Value

$2.70

Estimated upside of 6.8% versus the current market price.

Fair Value Confidence

Very low

Confidence level for the primary fair value estimate.

EPV Fair Value

$1.75

Earnings power value estimate.

Comps Fair Value

$2.86

Comparable-company valuation reference.

Analyst Price Target

$15.40

Analysts imply upside of 508.7%.

How to read these valuation models

Use the 5 available valuation references for CervoMed Inc (NASDAQ-CRVO) as analytical inputs, not a standalone conclusion. Valuation methods can differ because they rely on different assumptions, time horizons and financial inputs; compare the estimates with the current price and the company’s financial quality.

Profitability • Growth

Profitability & Growth for CervoMed Inc (NASDAQ-CRVO)

Review the profitability and growth indicators currently supported by the latest data.

Revenue

331.295 K

Current operating scale indicator.

Revenue Forecast

4.007 M

Forward revenue estimate.

EBITDA

-31.165 M

Current operating profitability reference.

EBITDA Forecast

-28.6 M

Forward operating profitability estimate.

How to read profitability and growth

This section helps investors review CervoMed Inc (NASDAQ-CRVO) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for CervoMed Inc (NASDAQ-CRVO)

Review the financial quality and risk indicators currently supported by the latest data.

Financial Health

Weak

Financial pressure deserves closer review.

Piotroski Score

2

Weak quality score that deserves closer review.

Altman Z-Score

-1.4

Lower score that deserves closer risk review.

FCF / Net Income

92.2%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for CervoMed Inc (NASDAQ-CRVO). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for CervoMed Inc (NASDAQ-CRVO)

Track the upcoming dates and dividend metrics currently supported by the latest data.

Next Earnings Date

November 16, 2026

Days to Earnings

55

Dividend Yield

0.0%

No current dividend yield is indicated.

How to read events and dividends

This section helps investors track time-sensitive items for CervoMed Inc (NASDAQ-CRVO), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

CervoMed Inc (NASDAQ-CRVO) Stock Forecast & Technical Outlook

Review CervoMed Inc (NASDAQ-CRVO) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Buy

The 15-minute technical read for CervoMed Inc (NASDAQ-CRVO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Buy

The 1-hour technical read for CervoMed Inc (NASDAQ-CRVO) is currently Strong Buy. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for CervoMed Inc (NASDAQ-CRVO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for CervoMed Inc (NASDAQ-CRVO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for CervoMed Inc (NASDAQ-CRVO) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for CervoMed Inc (NASDAQ-CRVO)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, CervoMed Inc (NASDAQ-CRVO) has a Strong Buy consensus, with 6 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 6
Hold 0
Sell 0
FAQ • Fast Investor Answers

CervoMed Inc (NASDAQ-CRVO) Stock FAQ

Data-supported answers about CervoMed Inc (NASDAQ-CRVO), including explicit coverage status where a reliable valuation estimate is not currently available.

Fair Value
$2.70
Estimated upside 6.8%
Valuation Rating
Undervalued
Estimated upside of 6.8%
Analyst Target
$15.40
Implied upside 508.7%
Financial Health
Weak
Current financial-health read

The current fair value estimate for CervoMed Inc (NASDAQ-CRVO) is $2.70. This implies an estimated upside of 6.8% versus the current market price.

Based on the current fair value estimate, the stock appears undervalued, with estimated upside of 6.8% versus the current market price.

The available analyst price target for CervoMed Inc (NASDAQ-CRVO) is $15.40. The analyst target implies estimated upside of 508.7%.

The current financial health read for CervoMed Inc (NASDAQ-CRVO) is Weak. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for CervoMed Inc (NASDAQ-CRVO) is November 16, 2026.

The latest available data indicates no current dividend yield for CervoMed Inc (NASDAQ-CRVO).

The current market capitalization listed for CervoMed Inc is 38.251 M.

The current enterprise value listed for CervoMed Inc is 13.313 M. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for CervoMed Inc is NASDAQ-CRVO, and the stock is listed on NASDAQ.

CervoMed Inc (NASDAQ-CRVO) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for CervoMed Inc is 0.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for CervoMed Inc is 63.5%. Free float helps investors understand how much of the share base is available for public trading.

Similar Biotechnology Stocks View more on NASDAQ

Comparable companies from the same industry, limited to one security per issuer.

ABBV NYSE AbbVie Inc Fair Value Fair Market Cap 468.7 B
AMGN NASDAQ Amgen Inc Fair Value Fair Market Cap 221.8 B
GILD NASDAQ Gilead Sciences Inc Fair Value Fair Market Cap 189.3 B
VRTX NASDAQ Vertex Pharmaceuticals Inc Fair Value Fair Market Cap 130.5 B
REGN NASDAQ Regeneron Pharmaceuticals Inc Fair Value Undervalued Market Cap 80.273 B
MRNA NASDAQ Moderna Inc Fair Value Overvalued Market Cap 72.885 B
ARGX NASDAQ argenx NV ADR Fair Value Fair Market Cap 61.249 B
NTRA NASDAQ Natera Inc Fair Value Overvalued Market Cap 56.346 B
ONC NASDAQ BeOne Medicines AG DRC Fair Value Fair Market Cap 41.851 B
RVMD NASDAQ Revolution Medicines Inc Fair Value Fair Market Cap 41.337 B
ALNY NASDAQ Alnylam Pharmaceuticals Inc Fair Value Fair Market Cap 33.673 B
BIIB NASDAQ Biogen Inc Fair Value Fair Market Cap 33.298 B
ROIV NASDAQ Roivant Sciences Ltd Fair Value Overvalued Market Cap 27.607 B
INSM NASDAQ Insmed Inc Fair Value Fair Market Cap 26.385 B
INCY NASDAQ Incyte Corporation Fair Value Fair Market Cap 25.728 B
BNTX NASDAQ BioNTech SE Fair Value Fair Market Cap 25.339 B
UTHR NASDAQ United Therapeutics Corporation Fair Value Fair Market Cap 21.342 B
GMAB NASDAQ Genmab AS Fair Value Overvalued Market Cap 20.853 B
ASND NASDAQ Ascendis Pharma AS Fair Value Fair Market Cap 15.602 B
NBIX NASDAQ Neurocrine Biosciences Inc Fair Value Undervalued Market Cap 14.46 B